Preclinical in vitro studies presented at ATS 2025 demonstrate that the combination of APG333 + APG777 prevents barrier loss induced by TSLP and IL-13 to a greater degree than benchmark anti-IL-4RA or anti-TSLP antibodies alone in a COPD lung epithelial cell model (91). This evidence concerns the gene IL13 and chronic obstructive pulmonary disease.